Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

December 30, 2020

The Top 10 Most Popular CURE® Stories of 2020

Author(s):

Jessica Skarzynski

Here are the top 10 stories from CURE® in 2020.

From using the lessons learned from cancer to cope with the stress of a pandemic, to self-advocacy and exploration, here’s a look back at the top 10 most popular CURE® stories of 2020:

10. Dealing With the Threat of Coronavirus as a Cancer Survivor

In this piece written back in March, CURE® contributor Laura Yeager talks about how, having lived with the possibility of early death as a two-time cancer patient, she is used to the coronavirus threat and all that it entails. “Having and ‘beating’ cancer has made me unafraid of other health threats,” she says.

9. Taking On The Extraordinary After Struggling With Early Breast Cancer

On a solo 10,000 mile, 25-state road trip with her emotional support cat, Cookie, Patrizza E. Jimenez examines what she learned from her experience with high-grade ductal carcinoma in situ. “I am getting stronger physically day by day, not only helping myself but finding a purpose in helping others by sharing the story of my journey. I do have a reason to live life fully as if there is no tomorrow.”

8. Finding Your Tribe After a Cancer Diagnosis

Cancer can feel lonely and isolated, but through the community, a person touched by the disease can enjoy camaraderie and support, as breast cancer survivor Bonnie Annis learned in this piece from January.

7. How COVID-19 Affects Patients with Cancer

As the new coronavirus (COVID-19) began its spread across the world in March, we took a closer look at how experts were working together to determine how it affects patients with cancer with this story.

6. Appendix Cancer: An Elusive Diagnosis

Often uncovered by accident, appendiceal cancers trigger few symptoms until they’re advanced and can be difficult to detect and treat. Learn more about it from experts and patients who have experienced it firsthand in this feature from our Rare Cancers Special Issue.

5. Dying to Talk

Discussing the possibility of dying is an unfortunate reality for many patients with cancer and their loved ones, but it isn't a talk that should be avoided. In this piece written by CURE® contributor and pancreatic cancer survivor William Ramshaw, learn how it can lead to more healing and understanding.

4. Refine and Retry, Getting Ovarian Cancer Treatment Right for Patients

One of the biggest challenges in ovarian cancer involves early detection, as it often presents with vague symptoms that can be overlooked not only by a patient but also by health care providers. Here, CURE®’s Editor-in-Chief, Dr. Debu Tripathy, weighs in on how the treatment and detection landscape needs to be refined to help patients with ovarian cancer.

3. Early Evidence Shows Fasting, Keto Diet May Make Chemo and Some Other Cancer Treatments More Effective and Easier to Tolerate

In this feature from our Fall 2020 issue, we take a look at early evidence that has found fasting, restricting calorie consumption or following the ketogenic diet could make chemotherapy and some other cancer treatments more effective and easier to tolerate.

2. Do You Understand Your Diagnosis?

Health literacy is important for any patient with cancer trying to understand their diagnosis, and they need help from their care team to gain that. In this piece written before her passing in June, CURE® Magazine co-founder and breast cancer survivor, Kathy LaTour, revisited her experience of learning about her diagnosis to demonstrate the importance of understanding your diagnosis.

1. With Rare Cancers, Progress Starts with the Patients

Some diagnoses are straightforward; others can take months or even years to pinpoint. That is why it is crucial for patients who know that something is not right to continue to follow up with their care team or seek out specialists. In our top story of the year, CURE® Chairman, Mike Hennessy Sr. examines how progress is happening in the rare cancer treatment landscape thanks to patients advocating for their care.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Minimally Invasive Surgery Transforms Lung Cancer Recovery
Image of man with text.
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Related Content
Advertisement
CURE spoke with experts about radical cystectomy for patients with bladder cancer: © stock.adobe.com.
August 2nd 2025

What Patients With Cancer Need to Know About Bladder Removal Surgery

Alex Biese
CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.
The Importance of Spotting Endometrial Cancer
August 2nd 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of man with text.
August 2nd 2025

Understanding Epithelioid Hemangioendothelioma: A Rare Vascular Cancer

Gina Mauro
Dr. Michael Wagner covers the basics of epithelioid hemangioendothelioma, a rare vascular cancer, spanning symptoms, diagnosis, treatment options and more.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
August 2nd 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
FDA sign.
August 2nd 2025

Oncolytic Virus Wins FDA Fast Track Designation in Soft Tissue Sarcoma

Ryan Scott
The U.S. FDA has granted fast track designation to treatment with CLD-201, an oncolytic virus, for patients with soft tissue sarcoma.
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 2nd 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.
Related Content
Advertisement
CURE spoke with experts about radical cystectomy for patients with bladder cancer: © stock.adobe.com.
August 2nd 2025

What Patients With Cancer Need to Know About Bladder Removal Surgery

Alex Biese
CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.
The Importance of Spotting Endometrial Cancer
August 2nd 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of man with text.
August 2nd 2025

Understanding Epithelioid Hemangioendothelioma: A Rare Vascular Cancer

Gina Mauro
Dr. Michael Wagner covers the basics of epithelioid hemangioendothelioma, a rare vascular cancer, spanning symptoms, diagnosis, treatment options and more.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
August 2nd 2025

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
FDA sign.
August 2nd 2025

Oncolytic Virus Wins FDA Fast Track Designation in Soft Tissue Sarcoma

Ryan Scott
The U.S. FDA has granted fast track designation to treatment with CLD-201, an oncolytic virus, for patients with soft tissue sarcoma.
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status: © stock.adobe.com.
August 2nd 2025

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

Spencer Feldman
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.